Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kerstin af Jochnick – new ECB representative to the Supervisory Board

The Governing Council of the European Central Bank (ECB) has appointed Kerstin af Jochnick as ECB representative to the Supervisory Board of ECB Banking Supervision.“I am very pleased to have been entrusted with the task of becoming independent member of the Supervisory Board of ECB Banking Supervision. The ECB's supervision of the larger banks in Europe plays a very important role in creating stable financial markets,” says First Deputy Governor Kerstin af Jochnick. Kerstin af Jochnick will therefore leave her post as First Deputy Governor of the Riksbank. The General Council of the

OUTOTEC OYJ: Change in the holding of the company’s own shares on July 11, 2019

OUTOTEC OYJ   STOCK EXCHANGE RELEASE   July 11, 2019 at 4:00 PM OUTOTEC OYJ: Change in the holding of the company’s own shares on July 11, 2019 On July 11, 2019 a total of 5,080 Outotec shares (OTE1V) have been returned to Outotec Oyj. The return is related to the company’s long-term share-based incentive plan. After the return, Outotec holds a total of 1,271,628 own shares. For further information please contact: OUTOTEC Jari Ålgars, CFOTel. +358 20 529 211DISTRIBUTION:NASDAQ HelsinkiMain mediawww.outotec.com

Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)

Oslo, Norway, 11 July 2019 Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation. The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation study designed to assess the safety, tolerability, pharmacokinetic profile and preliminary anti-tumour activity of a single administration of Betalutin®. Patients were enrolled at clinical trial sites in

Nokian Tyres’ US Factory Produces First Test Tire

Nokian Tyres, July 11, 2019 – The company’s North American production facility remains on schedule to begin producing tires for commercial use in early 2020.Nokian Tyres has produced the first test tire at its factory in Dayton, Tennessee, USA. The first tire, a Nokian eNTYRE 2.0 in size 205/55R16, marks the beginning of trial production, as Nokian Tyres remains on schedule to start building tires for commercial sale in the early part of next year. The Dayton Factory  will serve as a catalyst for Nokian Tyres’ growth strategy in North America;

Skanska signs new tenant lease at 99M in Washington, D.C., USA

Skanska has signed a lease for 11 years with CommonGrounds Workplace for approximately 4,100 square meters at its 99M office development in Washington, D.C., USA. The flexible workplace provider will take occupancy in spring 2020. With this transaction, the office portion of the development project is now 76 percent leased.99M is an 11-story, 22,000-square-meter, LEED® Gold, Class-A office development in Washington, D.C.’s Capitol Riverfront. Skanska began construction in July 2015 and completed construction in the second quarter of 2018. Skanska is one of the leading development and

Redsense Medical comments on the Trump initiative - potential impact on Redsense's business

President Donald Trump will order a broad overhaul of the nation’s organ transplant and kidney dialysis systems Wednesday in an executive order designed to prolong lives and to save the government billions of dollars, according to people familiar with the plan.President Trump will outline proposals to keep people with kidney disease off dialysis longer and to make treatment less expensive, to encourage more live donation of kidneys and livers, and to force the 58 non-profits that collect transplant organs to improve their performance, people briefed on the plan said. The President also will

Successful presentation by Cereno at ISTH in Melbourne - wins the "Top Poster" award

Cereno Scientific AB has recently participated in the annual major scientific conference on thrombosis related diseases ISTH in Melbourne, Australia, where interest in Cereno's drug candidate CS1 was great. The company's co-founder Pia Larsson, PhD presented Cereno's abstract "A New Treatment for Thrombosis Prevention?" in the form of a poster that received the award "Top Poster Winner".– It is always rewarding to meet the world's leading scientists and companies in the field and present our research to key stakeholders. Winning the prize Top Poster is an acknowledgment that our research is

Invitation to presentation of Q-linea’s Interim Report Q2-2019 on July 18, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 18, 2019 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on July 18, at 13:00 – 14:00 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Interim Report Report for the period January – June 2019 followed by a Q&A-session.   To participate, please call any of the following phone numbers from:Sweden: + 46 8 519 993 83UK: + 44 333 300

Half-yearly report, January – June 2019

Positive trend for cloud services and challenging quarter in Business Unit WestThe second quarter in brief · Revenues decreased by 7% to SEK 806 (868) million. The growth in local currencies was -8%. · Adjusted EBITA amounted to SEK 36.7 (54.8) million. Items affecting comparability amounting SEK -9.1 million refers to divestment of subsidiary. · Profit before tax decreased to SEK 22.3 (46.8) million. Adjusted for items affecting comparability profit before tax amounted to SEK 31.4 (46.8) million. · Profit after tax amounted to SEK 12.8 (35.2) million. · Profit per share

Q-FREE - TOLLING CONTRACT IN AUSTRALIA - 55 MNOK

Q-Free has been awarded a tolling contract in Australia. The contract has a value of approximately 55 MNOK and comprises roadside solutions as well as service and maintenance for one year. Most of the revenues will be booked in 2020.   More details will be disclosed during the second quarter presentation tomorrow. For further information, please contact: President & CEO, Håkon Volldal: +47 977 19 973 CFO, Tor Eirik Knutsen: +47 950 50 062   About Q-Free  Q-Free is a leading global supplier of ITS (Intelligent Transportation Systems) products and solutions. The company has

ALOGIC launches in the UK with two state of the art docking stations

ALOGIC, the Australian manufacturer of a range of high-quality PC and Mac peripheral equipment, has debuted in the UK with distributor Westcoast. Across a range of over 4,000 products, ALOGIC has carved out a reputation for elegant, design-led hardware that still delivers on the levels of functionality and reliability expected by customers, with a two-year warranty across the board and 24 hour phone support available. This ethos is the perfect match for the service-led approach of Westcoast and brings pan European availability to the ALOGIC product range. ALOGIC’S arrival in the UK

Leading US proton center selects RayStation for treatment planning

The James M. Slater, MD Proton Treatment and Research Center at Loma Linda University Medical Center, US, has chosen the treatment planning system (TPS) RayStation®* to replace its existing systems for photon and proton therapy planning, following a tender process.The James M. Slater, MD Proton Treatment and Research Center is a cutting-edge facility that focuses on using advanced technology to deliver the best possible patient care. The center has treated more than 17,500 proton patients, more than any other facility in the world. To support the center's ongoing mission of providing the

REMEDY ENTERTAINMENT PLC: Board of Directors decided on a new option plan

Remedy Entertainment Plc | Company announcement 1.30 p.m. (EET) 11 July 2019 Board of Directors decided on a new option plan The Board of Directors of Remedy Entertainment Plc has, by virtue of the authorization granted by the Annual General Meeting held on April 8, 2019, decided to adopt an option plan “Option Plan 2019” directed to the key persons as decided separately by the Board of Directors. There is a weighty financial reason to issue the option rights as the option plan is a part of the company’s incentive and commitment scheme for key persons. The maximum total number of

IAAM brings research and industry closer together: Swedish organization hosts worldwide scientific congresses on cruise ships

Between 10–13th of June the 26th assembly of Advanced Materials Congress (AMC) was organized onboard Viking Line’s M/S Mariella, sailing from Stockholm to Helsinki. Scientists, researchers and business executives from over 50 countries gathered to present and discuss findings and breakthroughs. The host, International Association of Advanced Materials (IAAM) is investing in new breakthroughs with the aim of bringing research and industry closer together. In the upcoming autumn and winter international congresses are arranged in Singapore, Orlando, USA and Sydney, Australia.The opening

Hatch, the first cloud gaming service for mobile in Italy, launches together with Vodafone and the power of 5G internet connection

July 10 - Vodafone Italy and Hatch are launching the new cloud gaming mobile platform compatible with 5G internet connection. An exclusive partnership that, thanks to the low latency and to the high capacity of data transfer of Vodafone Giga Network 5G, offers Italian gamers a truly revolutionary gaming experience. Vodafone users will be able to play for free during the first three months after the launch of the service, then they can get access to more than 100 games for just €6,99 monthly. Thanks to the innovative characteristics of Giga Network 5G, Italian users will be able to

Invitation to Kongsberg Automotive's Q2 2019 Earnings Call

Kongsberg Automotive ASA will release its second quarter 2019 results on Friday July 26th 2019 at 07:30 am CET. The company will host an earnings conference call for investors, analysts and media at 09:00 CET, on July 26th, which will include a review of the Q2 2019 presentation. After the review, listeners can ask questions to the presenters.   The Q2 earnings conference call will be available via web and audio, and to access the audio webcast please select one of the options below: 1. Web access: Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1231903&tp_key=fb96795a80

CELLINK has been granted a patent for "Clean chamber technology for 3D Printers and Bioprinters" from the Korean Intellectual Property Office

CELLINK has been granted a patent for a unique technology enabling bioprinting in a clean environment. The patent protection applies to the Korean market, the company also conducts the process of expanding patent protection in additional countries. The patent protection from the Korean Intellectual Property Office shows uniqueness and height of innovation. This technology is used in CELLINK’s flagship bioprinter the BIO X and the INKREDIBLE+ to enable true desktop printing and ensuring sterility during the printing process. “We are extremely excited to have another granted patent for

Press release: Nel launches the A1000 electrolyzer

Nel Hydrogen Electrolyser, a subsidiary of Nel ASA, today officially launched the A1000 alkaline electrolyzer “After working with large-scale solutions for our alkaline electrolyzers, we have now designed a new medium scale, 2 ton/day solution. It is a pleasure to now officially include this product in our electrolyzer offering,” says Anders Søreng, CTO of Nel. The A1000 builds on the industry leading A-Range atmospheric alkaline platform, and comes in the size range of 600 to 970 Nm3/hr, allowing for flexible scale-up according to customer demand. “We are paying close attention to

Interview with 2018 Eklund Foundation grantees Jan Derks and Tord Berglundh

Jan Derks and Tord Berglundh from the Institute of Odontology at the University of Gothenburg in Sweden recently received funding amounting to SEK 930,000 from the Eklund Foundation for their study “Periodontitis, Peri-implantitis and Diabetes - a registry study”. The two researchers gave an interview at their visit to TePe Oral Hygiene Products AB in Malmö, Sweden, in June 2019. Since its establishment in 2015, the Eklund Foundation has distributed funds of approximately SEK 4.5 million to high-quality research in dentistry. The foundation was created by the Eklund family, which also

STENOCARE receives new information from CannTrust that causes immediate quarantine on sales of products from current inventory

Contrary to the information that STENOCARE first received from its partner and supplier, CannTrust, about the origin of product batches supplied by CannTrust, STENOCARE has early this morning received additional documentation from CannTrust that indicates that an additional part of the products in STENOCAREs inventory, which has been sold to the market since June 10, 2019 were sourced from the production rooms at CannTrust, that were not yet approved at the time of production. STENOCARE is in dialogue with the Danish Medicines Agency about this new situation.Early this morning, STENOCARE

Climeon one of 100 innovations with greatest potential to reduce carbon dioxide emissions

Climeon has been selected as a top 100 innovative solution provider with a large potential to significantly reduce carbon dioxide emissions by Mission Innovation, a global initiative consisting of 24 countries and the European Commission. The solutions were presented as a part of the 1.5°C Compatible Solutions Framework aiming to help investors identify technologies with the largest potential to tackle climate change.In 2015, more than 190 countries agreed to adopt Agenda 2030, the most ambitious agreement for sustainable development that world leaders have ever made. With these global

Miris HMA™ installed in Singapore to provide invaluable help for premature babies

Miris announces the official release and Singapore's first clinical installation of Miris Human Milk Analyzer™ (Miris HMA™) at the milk bank KK Women’s and Children’s Hospital in Singapore. For the first time doctors in Singapore now have access to a diagnostic test to analyze the nutrients in human milk, which is crucial in the case of extreme premature or sick babies with particular nutritional needs.The Miris HMA™ enables the KK Human Milk Bank – the only Milk bank in Singapore - to perform a diagnostic test to measure nutrients in human milk. The KK Milk Bank supports the NICUs at KK

RaySearch receives FDA clearance for RayStation 8B including machine learning functionalities

RaySearch has received 510(k) clearance from the FDA in the USA for version 8B of the treatment planning system RayStation®. RayStation 8B was released in December 2018 and includes the first machine learning applications in a treatment planning system on the radiation oncology market today.The machine learning applications for automated treatment planning and automated organ segmentation in RayStation help improve efficiency and consistency in the clinic. The machine learning framework allows for models to be trained on the clinic’s available data, and it is also possible to use pre-

Northmill Group publishes bond prospectus and applies for listing of the bonds on Nasdaq Stockholm

Stockholm, Sweden 11 July at 10:00 CETNorthmill Group AB (publ) (“Northmill Group” or the “Company”) has issued senior unsecured bonds of SEK 500,000,000 on 3 September 2018, within a total framework amount of SEK 1,000,000,000 on the Swedish bond market (the "Bonds"). The Company will apply for listing of the bonds on the Corporate Bond list on Nasdaq Stockholm and has in connection thereof prepared a prospectus which today has been approved by the Swedish Financial Supervisory Authority (the “SFSA”).  The tenor of the bonds is three (3) years. The bonds carry a floating interest rate

There are no items matching the current filter
There are no more items matching the current filter
Back to top